Jaguar health provides company updates and reports 2022 third quarter financials

Prescription product net revenue of approximately $3.1 million in q3 2022 increased 8.2% over q2 2022 and increased approximately 412% over prescription product net revenue in q3 2021 core initiatives: ontarget phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) adding international sites, targeting completion of enrollment in q2 2023 publication of phase 2 iit study in peer reviewed journal breast cancer research and treatment expected presentation in december 2022 from a third-party investigator, dr. mohamad miqdady, division chief of the pediatric gastroenterology, hepatology & nutrition division at sheikh khalifa medical city in abu dhabi, following initiation of proof-of-concept trial of crofelemer for short bowel syndrome (sbs) and congenital diarrheal disorders (ccd), supporting the potential for expanded patient access through programs in europe in 2023 second conditional approval for canalevia®, for exercise-induced diarrhea (eid), expected in q1 2023, adding to ongoing commercial activities of canalevia-ca1 for treatment of chemotherapy-induced diarrhea (cid) in dogs business development activities with nondilutive funding for jaguar's mental health entheogen therapeutics initiative (eti) program targeted for q1 2023 jaguar's canine cancer: take c.h.a.r.g.e. registry honored by the marcom awards program with two platinum awards and one gold award reminder: jaguar to host investor webcast monday, november 14th at 8:30 a.m.
JAGX Ratings Summary
JAGX Quant Ranking